Michael Swope, APRN
Family · Princeton, MENPI 1184326787
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,514 of the $1,740 with a category attached, or 87.0%. 17 manufacturers reported payments, led by Novo Nordisk at 24.4% of the total. Among family clinicians in ME with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 87 payments — averaging $20.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$424
- Lundbeck LLC$298
- AstraZeneca$192
- Pfizer$129
- Exact Sciences$111
- Otsuka America Pharmaceutical, Inc.$100
- plus $486 from 11 others
What the payments were for
- Food & beverage$1,51487%
- Education$22613%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 19 | $424 |
| Lundbeck LLC | 13 | $298 |
| AstraZeneca | 9 | $192 |
| Pfizer | 7 | $129 |
| Exact Sciences | 6 | $111 |
| Otsuka America Pharmaceutical, Inc. | 5 | $100 |
| GSK | 6 | $92 |
| Merck | 5 | $87 |
| Teva Pharmaceuticals USA, Inc. | 4 | $70 |
| Boehringer Ingelheim | 3 | $54 |
| Astellas Pharma US Inc | 2 | $41 |
| Lilly USA, LLC | 2 | $38 |
| Bayer | 2 | $31 |
| Alkermes, Inc. | 1 | $20 |
| Aimmune Therapeutics, Inc. | 1 | $20 |
| AbbVie | 1 | $17 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $15 |
How this compares
$1,740 in reported general payments places this provider in the 90th percentile of 545 family providers in Maine.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RybelsusSemaglutide | 16 | $38,230 |
| EliquisApixaban | 17 | $23,694 |
| JardianceEmpagliflozin | 18 | $19,782 |
| OzempicSemaglutide | 15 | $16,130 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 16 | $14,924 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 15 | $12,291 |
| Pregabalin | 45 | $2,405 |
| Rosuvastatin Calcium | 37 | $1,308 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 44 | $1,275 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 45 | $1,033 |
| Atorvastatin Calcium | 53 | $1,014 |
| Duloxetine Hcl | 12 | $969 |
| Levothyroxine Sodium | 45 | $957 |
| Gabapentin | 45 | $838 |
| Oxycodone Hcl | 43 | $722 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskRybelsus, Ozempic | $424 | $54,36031 claims |
| PfizerEliquis | $129 | $23,69417 claims |
| Boehringer IngelheimJardiance | $54 | $19,78218 claims |
| GSKTrelegy Ellipta | $92 | $14,92416 claims |
| AstraZenecaBreztri Aerosphere | $192 | $12,29115 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 545 family providers in Maine.
Other family in Princeton
- Phylicia BonavidaPrinceton$2K
- Tara DwelleyPrinceton$2K
- Mia RapollaFalmouth$193K
- Patti DupreyKennebunk$35K
- Amanda WilliamsPortland$8K
- Jamie PiacentiniScarborough$6K
- Rosemary PainePortland$6K
- Brea SwihartAugusta$5K
- Kristen Schroeder-CyrBrunswick$5K
- Liana KellyBrunswick$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.